GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting

  • Preclinical data on GMI-1271 in four oral presentations and one poster focus on blood cancers and coagulation disorders
  • New data for rivipansel, sickle cell investigational drug candidate, show effects on biomarkers
ASH 2014

GAITHERSBURG, Md.--()--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that data from two drug candidates in its clinical pipeline, GMI-1271 and rivipansel (formerly known as GMI-1070), will be featured during four oral presentations and two poster sessions at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is being held December 6-9, 2014, at the Moscone Center in San Francisco.

GMI-1271, an E-selectin antagonist, is currently in a Phase 1 clinical trial for blood cancers with elevated risk of thrombosis. The company has already completed a Phase 1 clinical trial of GMI-1271 in healthy volunteers. GlycoMimetics is planning to conduct a clinical trial to evaluate treatment with GMI-1271 in patients with acute myeloid leukemia and expects to begin recruiting patients during the fourth quarter of 2014. Rivipansel, which has received both Orphan Drug and Fast Track designation from the U.S. Food & Drug Administration (FDA) for the treatment of vaso-occlusive crisis in sickle cell disease, as well as Orphan Product designation in the European Union, is being developed under a licensing and collaboration agreement with Pfizer, Inc.

“Selection of four abstracts on GMI-1271 for oral presentations at the ASH annual meeting demonstrates the potential impact of this novel and differentiated approach to treating blood diseases. The preclinical data being presented will highlight the scientific rationale for moving this drug candidate into further clinical testing,” said Rachel King, CEO of GlycoMimetics.

Specifics of the abstracts, including session times and locations, include:

  • “Mobilization of Reconstituting HSC Is Boosted By Synergy Between G-CSF and E-Selectin Antagonist GMI 1271.” [Session 711. Cell Collection and Processing: Preclinical News], Monday, December 8, 2014, 8:00 AM, Moscone Center, West Building, 3018-3020
  • “The Vascular Niche is Involved in Regulating Leukemic Stem Cells in Murine Chronic Myelogenous Leukemia.” [Session 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Disease Progression and the Microenvironment: Therapeutic Implications], Monday, December 8, 2014, 4:00 PM, Moscone Center, West Building, 3018-3020
  • “Vascular Niche E-Selectin Protects Acute Myeloid Leukemia Stem Cells from Chemotherapy.” [Session 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation I], Monday, December 8, 2014, 4:45 PM, Moscone Center, South Building, Gateway Ballroom 103
  • “E-Selectin Inhibitor GMI-1271 Works in Combination with Low-Molecular Weight Heparin to Decrease Venous Thrombosis and Bleeding Risk in a Mouse Model.” [Session 332. Antithrombotic Therapy: Venous Thromboembolism], Monday, December 8, 2014, 5:30 PM, Moscone Center, West Building, 3006-3008
  • “Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model.” [Session 652: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III], Monday, December 8, 2014, 6:00 PM – 8:00 PM, Moscone Center, West Building, Level 1
  • “Pan Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis.” [Session 114. Hemoglobinopathies, Excluding Thalassemia – Clinical: Poster II], Sunday, December 7, 2014, 6:00 PM – 8:00 PM, Moscone Center, West Building, Level 1

The meeting abstracts are available via ASH's website.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Pfizer, the company’s development partner for rivipansel, a GlycoMimetics-developed investigational therapy for pain crisis associated with sickle cell disease, is preparing for a Phase 3 clinical study. A GlycoMimetics wholly-owned candidate therapy for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. GlycoMimetics’ lead drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease and will be studied in a Phase 3 clinical trial to be conducted by Pfizer Inc., the company’s collaborator for rivipansel. GlycoMimetics’ drug candidate GMI-1271, a novel and proprietary E-selectin antagonist, is being developed as a potential therapy for acute myeloid leukemia (AML) and other blood disorders and is being studied in a Phase 1 clinical trial. Learn more at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding the clinical development of rivipansel and GMI-1271. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s quarterly report on Form 10-Q that was filed with the U.S. Securities and Exchange Commission on October 31, 2014, and other filings the Company makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.


GlycoMimetics, Inc.
Brian Hahn, 240-243-1207


GlycoMimetics, Inc.
Brian Hahn, 240-243-1207